Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C -

- Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events versus peginterferon alfa-2a -

- Filing of global marketing applications planned in fall 2009 -

ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"These Phase 3 data show that, with half the injections, the efficacy of Albuferon was comparable to Pegasys," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We are pleased that Albuferon met its primary endpoint in the ACHIEVE 1 trial as it also did in ACHIEVE 2/3. We look forward to the filing of global marketing applications in fall 2009, following discussions with regulatory authorities. Assuming licensure, we believe Albuferon could become a market-leading treatment for chronic hepatitis C."

Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany, s
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... UBM Canon Medical Device Media Group,s ... the " Technological Advances in Implantable Devices " virtual event ... 5 p.m. Eastern.  The event is dedicated to cutting-edge trends ... conference and trade show offers the opportunity to learn from ...
... N.J., Feb. 1, 2011 Soligenix, Inc. (OTC Bulletin ... a late-stage biopharmaceutical company, announced today that it has ... and Chief Medical Officer. Dr. Horgan is a board-certified ... experience in the care of patients with inflammatory bowel ...
Cached Medicine Technology:UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 2UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... 2014 Pathways Home Health & ... This national movement was created to encourage people to ... local charities and causes. This online event, celebrated ... kickoff of the holiday shopping season. #GivingTuesday is to ... Cyber Monday is to online commerce. , The goal ...
(Date:11/28/2014)... is always making changes to its infrastructure architecture as ... effective, and secure experience. Most recently, the company announced ... to setup local servers for each country or continent. ... the globe. , 2. The ability to setup a ... millions of users in one network. , 3. The ...
(Date:11/28/2014)... November 28, 2014 Junk-A-Car ( http://www.junkacar.com ... expanding their service offerings to help drivers, especially those ... and Washington, D.C. metropolitan areas deal with the especially ... a large part of the country. , With the ... in hundreds of totaled, crashed and junk ...
(Date:11/28/2014)... Novatus, a leading provider of contract ... provides customers with greater reporting capabilities, more searchable ... we continue to evolve and grow the Novatus ... improved performance in response to requests from our ... the enhancements that we have made to Advanced ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2
... Swedish medical university Karolinska Institutet have determined the first ... interaction between the mammalian egg coat and sperm. The ... glimpse into the molecular architecture of animal egg coats, ... medicine and the possibility of developing novel contraceptives. , ...
... skin, intestinal mucosa or blood, have a lifespan of only ... replenishment of specialized cells is indispensable. This is the task ... cells. , Stem cells have two main characteristics: ... cell types that make up their respective tissue a ...
... AARP CEO Bill Novelli today released the following statement in ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ... are in dire economic times that will only get worse ... immediate choice is between letting these corporations go under -- ...
... 4 Cardinal Health and the,Texas Hospital Association (THA) ... to safeguard patients and combat deadly health care associated,infections ... Texas Hospital Association and its marketing subsidiary, HealthShare,recently endorsed ... help combat HAIs, improve patient care and dramatically reduce,infection-related ...
... Getting back in the gym and,erasing years of ... amounts of,weight because your health depends on it is ... joining forces with NBC,s hit weight loss,program The ... of,their lives by creating a co-branded protein product, The ...
... Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Food and Drug Administration (FDA) Premarket Approval (PMA) for the ... designed to enhance cervical cancer screening for cytology laboratories using ... squamous carcinoma, adenocarcinoma and their usual precursor conditions. ...
Cached Medicine News:Health News:Crystallography reveals the 3-D structure of mammalian sperm receptor 2Health News:Dormant stem cells for emergencies 2Health News:Dormant stem cells for emergencies 3Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 3Health News:Texas Hospital Association Endorses MedMined(TM) Services to Help Fight Hospital Acquired Infections 2Health News:Texas Hospital Association Endorses MedMined(TM) Services to Help Fight Hospital Acquired Infections 3Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 2Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 3Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 4Health News:BD Receives FDA Approval for the BD FocalPoint(TM) GS Imaging System to Enhance the Detection of Cervical Cancer 2
... a floor model centrifuge to do, but just ... PR-7000M delivers up to 50% more force in ... faster and more efficiently., Tremendous Capacity ... liters, PR-7000M accommodates 30 microplates, up to 408 ...
Inquire...
Inquire...
Inquire...
Medicine Products: